|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
On the basis of previous work in our laboratory, NAP, a 6β- N-4'-pyridyl substituted naltrexamine derivative, was identified as a peripheral MOR antagonist that may be used to treat OIC.
|
30608693 |
2019 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Peripherally acting μ-opioid receptor antagonist has been shown to be effective and durable for patients with OIC and is the only drug with confirmed evidence in meta-analysis.
|
30597600 |
2019 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Naldemedine is a novel peripherally acting μ-opioid receptor antagonists being developed for the treatment of OIC without affecting central analgesia.
|
30652502 |
2019 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Previously, naldemedine, a peripherally acting μ-opioid receptor antagonist demonstrated efficacy in the treatment of OIC.
|
31145214 |
2019 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Naldemedine (S-297995) is a peripherally acting μ-opioid receptor antagonist developed as a once-daily oral drug for opioid-induced constipation (OIC) in adults with chronic noncancer or cancer pain.
|
30821019 |
2019 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Naldemedine is a peripherally acting μ-opioid receptor antagonist that has been recently studied in randomized controlled trials (RCTs) for the management of OIC.
|
30851171 |
2019 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Naldemedine tosylate, a peripherally acting μ-opioid receptor antagonist, is indicated for treatment of opioid induced constipation in both Japan and US.
|
30770183 |
2019 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In a systematic review and meta-analysis, we found μ-opioid-receptor antagonists to be safe and effective for the treatment of OIC.
|
29374616 |
2018 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Naldemedine (S-297995) is a peripherally acting μ-opioid receptor antagonist for the treatment of opioid-induced constipation, a common side effect of opioid therapy.
|
28960888 |
2018 |
|
Opioid-Induced Constipation
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.
|
29504415 |
2018 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Naloxegol is a peripherally acting μ-opioid receptor antagonist that was developed for the treatment of opioid-induced constipation.
|
28548207 |
2017 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We investigated the efficacy and safety of a peripherally acting μ-opioid receptor antagonist, naldemedine (S-297995), for OIC, specifically in patients with cancer.
|
28968171 |
2017 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Naloxegol is a peripherally acting μ-opioid receptor antagonist approved as an orally administered tablet for the treatment of opioid-induced constipation.
|
28127938 |
2017 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Recently our laboratories have identified one novel lead compound, 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)acetamido]morphinan (NAP), as a peripherally selective mu opioid receptor ligand carrying subnanomolar affinity to the mu opioid receptor and over 100-folds of selectivity over both the delta and kappa opioid receptors, with reasonable oral availability and half-life, and potential to treat OIC.
|
28105279 |
2017 |
|
Opioid-Induced Constipation
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Naloxegol is an oral peripherally acting μ-opioid receptor antagonist approved for the treatment of opioid-induced constipation.
|
28504549 |
2017 |